EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer

Xinan Sheng iD, Gongqian Zeng, Cuijian Zhang, Qingyun Zhang, Jiasheng Bian, Haitao Niu, Jun Li, Yanxia Shi, Kai Yao, Bin Hu, Ziling Liu, Hong Liao und 20 weitere

New England Journal of Medicine · 11.12.2025 · 393 (23) · 2324-2337

DOI: 10.1056/nejmoa2511648 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 11.12.2025. Verfasst von Xinan Sheng und 31 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Genitourinary Oncology, Peking University Cancer H…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Immunoconjugates, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the Beijing Natural Science Foundation, RemeGen Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsImmunoconjugatesErb-b2 Receptor Tyrosine KinasesUrologic NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedCarboplatinCisplatinDeoxycytidineGemcitabineProgrammed Cell Death 1 ReceptorProgression-Free SurvivalUrotheliumFollow-Up StudiesAntibodies, MonoclonalOligopeptides

Substanzen

Antibodies, Monoclonal, HumanizedCarboplatinCisplatinDeoxycytidineGemcitabineImmunoconjugatesProgrammed Cell Death 1 ReceptorErb-b2 Receptor Tyrosine KinasesAntibodies, MonoclonalOligopeptides

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing.
  • Hunan Cancer Hospital, Changsha, China.
  • Peking University First Hospital, Beijing.
  • Affiliated Cancer Hospital of Guangxi Medical University, Nanning, China.
  • Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
  • Affiliated Hospital of Qingdao University, Qingdao, China.

ORCID-Profile: Xinan Sheng

Förderung

  • National Natural Science Foundation of China
  • the Beijing Natural Science Foundation
  • RemeGen Co., Ltd.

Zitieren

APA

Sheng, X., Zeng, G., Zhang, C., Zhang, Q., Bian, J., Niu, H., Li, J., Shi, Y., Yao, K., Hu, B., Liu, Z., Liao, H., Yu, Z., Jin, B., Zhao, P., Yang, T., Liu, X., Qin, Y., Xue, X., …, & RC48-C016 Trial Investigators (2025). Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. New England Journal of Medicine, 393(23), 2324-2337. https://doi.org/10.1056/nejmoa2511648

Vancouver

Sheng X, Zeng G, Zhang C, Zhang Q, Bian J, Niu H, et al. Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. New England Journal of Medicine. 2025;393(23):2324-2337. doi:10.1056/nejmoa2511648

BibTeX
@article{Sheng2025,
  author = {Sheng, Xinan and Zeng, Gongqian and Zhang, Cuijian and Zhang, Qingyun and Bian, Jiasheng and Niu, Haitao and Li, Jun and Shi, Yanxia and Yao, Kai and Hu, Bin and Liu, Ziling and Liao, Hong and Yu, Zhixian and Jin, Baiye and Zhao, Peng and Yang, Tiejun and Liu, Xianling and Qin, Yang and Xue, Xueyi and Gou, Xin and Huang, Jian and Gu, Jiang and Qi, Xiaolong and Zhang, Lu and Ma, Guoxian and Liu, Beisong and Fang, Jianmin and Jiang, Shusuan and He, Zhisong and Zhou, Aiping and Guo, Jun and RC48-C016 Trial Investigators, RC48-C016 Trial Investigators},
  title = {Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {23},
  pages = {2324--2337},
  doi = {10.1056/nejmoa2511648}
}
Kostenlos starten →